5.59

3.62% -0.21

Aprea Therapeutics Inc (APRE)

Overview News Price History Financials Discussions Forecast Stock Split

Aprea Therapeutics Inc stock is currently priced at $5.59, with a 24-hour trading volume of 14,739. It has seen a -3.62% decreased in the last 24 hours and a -4.44% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $5.75 pivot point. If it approaches the $5.43 support level, significant changes may occur.

Previous Close:

$5.80

Open:

$5.8

24h Volume:

14,739

Market Cap:

$30.35M

Revenue:

Net Income/Loss:

$-14.29M

P/E Ratio:

-1.0108

EPS:

-5.53

Net Cash Flow:

$-12.27M

1W Performance:

+1.64%

1M Performance:

-4.44%

6M Performance:

+49.07%

1Y Performance:

+43.81%

1D Range:

$5.331

$5.90

52W Range:

$2.78

$8.8465

Aprea Therapeutics Inc Stock (APRE) Company Profile

Name

Aprea Therapeutics Inc

Sector

Healthcare (1211)

Industry

Biotechnology (697)

Phone

617 463 9385

Address

3805 Old Easton Road, Doylestown, MA

Employee

Twitter

Next Earnings Date

2024-06-13

Latest SEC Filings

APRE's Discussions on Twitter

Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-28-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	Berenberg	Buy
Sep-29-20	Resumed	JP Morgan	Neutral
Jun-22-20	Initiated	H.C. Wainwright	Neutral
Apr-21-20	Initiated	Robert W. Baird	Outperform
Oct-28-19	Initiated	JP Morgan	Neutral
Oct-28-19	Initiated	Morgan Stanley	Equal-Weight
Oct-28-19	Initiated	RBC Capital Mkts	Outperform

View All

Aprea Therapeutics Inc Stock (APRE) Latest News

ArriVent BioPharma Bolsters Board with Biopharmaceutical Expert Dr. John Hohneker - MyChesCo

MyChesCo

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update - Defense World

Defense World

Learn to Evaluate (APRE) using the Charts - Stock Traders Daily

Stock Traders Daily

Aprea Therapeutics Announces Positive First Quarter Developments and FDA Clearance for Cancer Drug Trials - MyChesCo

MyChesCo

Aprea Therapeutics' (APRE) Outperform Rating Reaffirmed at Wedbush - Defense World

Defense World

Aprea Therapeutics' (APRE) Buy Rating Reaffirmed at HC Wainwright - Defense World

Defense World

Aprea Therapeutics Inc Stock (APRE) Financials Data

Aprea Therapeutics Inc (APRE) Net Income 2024

APRE net income (TTM) was -$14.29 million for the quarter ending December 31, 2023, a +87.32% increase year-over-year.

Aprea Therapeutics Inc (APRE) Cash Flow 2024

APRE recorded a free cash flow (TTM) of -$12.27 million for the quarter ending December 31, 2023, a +50.94% increase year-over-year.

Aprea Therapeutics Inc (APRE) Earnings per Share 2024

APRE earnings per share (TTM) was -$3.99 for the quarter ending December 31, 2023, a +95.90% growth year-over-year.

Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that target a critical pathway and various central targets in DNA damage response and cancer progression. Its lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor being developed for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.